Chemotherapeutic Nanoparticle-Based Liposomes Enhance the Efficiency of Mild Microwave Ablation in Hepatocellular Carcinoma Therapy.
combination therapy
enhance
hepatocellular carcinoma
liposomes
microwave ablation
nanoparticles
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
10
2019
accepted:
27
01
2020
entrez:
17
3
2020
pubmed:
17
3
2020
medline:
17
3
2020
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer, and the 5-year overall survival (OS) rate for HCC remains unsatisfying worldwide. Microwave ablation (MWA) is a minimally invasive therapy that has made progress in treating HCC. However, HCC recurrence remains problematic. Therefore, combination therapy may offer better outcomes and enhance MWA efficiency through improved tumor control. We have developed doxorubicin-loaded liposomes (DNPs) as an efficient nanoplatform to enhance MWA of hepatocellular carcinoma even at the mild ablation condition. In this study, we demonstrated that the uptake of DNPs by HCC cells was increased 1.5-fold compared with that of free DOX. Enhanced synergism was observed in the combination of DNPs and MWA, which induced nearly 80% cell death. The combination of mild MWA and DNPs enhanced the ablation efficiency of HCC with significant inhibition of liver tumors and accounted for the longest survival rate among all groups. A much higher accumulation of the DNPs was observed in the transitional zone than in the ablation zone. No apparent systemic toxicity was observed for any of the treatments after 14 days. The present work demonstrates that DNPs combined with MWA could be a promising nanoparticle-based therapeutic approach for the treatment of hepatocellular carcinoma and shows potential for future clinical applications.
Identifiants
pubmed: 32174827
doi: 10.3389/fphar.2020.00085
pmc: PMC7054279
doi:
Types de publication
Journal Article
Langues
eng
Pagination
85Informations de copyright
Copyright © 2020 Wu, Zhang, Yu, Dou, Li, Mu and Liang.
Références
Int J Hyperthermia. 2019;36(1):244-252
pubmed: 30668189
Radiology. 2010 Apr;255(1):62-74
pubmed: 20160000
Mol Pharm. 2019 Feb 4;16(2):779-785
pubmed: 30604617
Am J Surg. 2019 Mar;217(3):541-545
pubmed: 30782316
Drug Deliv. 2019 Dec;26(1):416-432
pubmed: 30929527
J Control Release. 2012 Jun 10;160(2):239-44
pubmed: 22230341
Nano Lett. 2019 May 8;19(5):2914-2927
pubmed: 30929452
Nanoscale. 2019 Mar 21;11(12):5717-5731
pubmed: 30865744
Nanoscale. 2017 Aug 10;9(31):11068-11076
pubmed: 28741635
Radiology. 2017 Nov;285(2):462-471
pubmed: 28631963
Can J Gastroenterol Hepatol. 2018 Jun 3;2018:4756147
pubmed: 29974040
Nanoscale. 2018 Aug 23;10(33):15677-15685
pubmed: 30091769
J Control Release. 2014 Jan 28;174:109-16
pubmed: 24287101
Int J Hyperthermia. 2018 Feb;34(1):59-67
pubmed: 28540809
Presse Med. 2017 Apr;46(4):381-385
pubmed: 28081946
Recent Pat Drug Deliv Formul. 2016;10(3):177-183
pubmed: 27712569
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
ACS Appl Mater Interfaces. 2019 Mar 27;11(12):11251-11261
pubmed: 30874421
Future Oncol. 2017 Jul;13(16):1437-1448
pubmed: 28685607
Nat Rev Cancer. 2014 Mar;14(3):199-208
pubmed: 24561446
ACS Nano. 2014 Jun 24;8(6):6004-13
pubmed: 24806291
Lancet Gastroenterol Hepatol. 2017 Jun;2(6):387-389
pubmed: 28497748
Int J Hyperthermia. 2016 May;32(3):339-44
pubmed: 26794414
J Hepatol. 2018 Jul;69(1):60-69
pubmed: 29471013
Radiology. 2018 Jul;288(1):300-307
pubmed: 29688153
Int J Hyperthermia. 2019 Jan 1;35(1):122-132
pubmed: 30300036
Gut. 2017 Jun;66(6):1172-1173
pubmed: 27884919
Radiology. 2016 Jun;279(3):762-72
pubmed: 26785043